Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly LY2189265 versus sitagliptin in type 2 diabetes mellitus on metformin
2007-007198-21Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2008
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dulaglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in HbA1c from baseline at 12 months. Started Jul 2008; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-007198-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007198-21.